DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Lixivaptan
Lixivaptan
Therapeutic Potential of Vasopressin-Receptor Antagonists in Heart Failure
Hypernatremia: 2 Months Back When He Had Progressive Decrease in Vision (Right > Left)
"Hyponatremia"[Text Word]) OR "Hyponatremic"[Text Word]
Vaptans and the Treatment of Water-Retaining Disorders Friedericke Quittnat and Peter Gross
The Structure and Function of V1b Vasopressin Receptor
Management of Hyponatremia
(CRDAC) Meeting Date: 13 September 2012
Olive Leaf Extract (OLE) Impaired Vasopressin-Induced Aquaporin-2
Download Product Insert (PDF)
Diagnosis and Treatment of Hyponatremia: Compilation of the Guidelines
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
The Treatment of Vasopressin V2-Receptor Antagonists in Cirrhosis Patients with Ascites
Vasopressin Antagonists in the Treatment of Water-Retaining Disorders
Lixivaptan: a Vasopressin Receptor Antagonist for the Treatment of Hyponatremia
Table S1: Clinical Trials of AVP Antagonists and Agonists
Appendix 2|Review Questions – PICOM Format Chapter 1
When Is It Appropriate to Use Vasopressin Receptor Antagonists?
The Syndrome of Inappropriate Antidiuretic Hormone: Current And
Top View
(V2)- Receptor Antagonist, in Mouse P
View Eposter
Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells
Uterine Drugs
Vasopressin Antagonists in Treatment of Hyponatremia
BMH Medical Journal 2015;2(4):106-109 Brief Review Vaptans
When Is It Appropriate to Use Vasopressin Receptor Antagonists?
Pharmacologic Chaperones As a Potential Treatment for X-Linked Nephrogenic Diabetes Insipidus
The La Tarde Dine Hii Na Kuwa Na Matatu
ADPKD) Using Quantitative Systems Toxicology Modeling Woodhead, J.L.*, Pellegrini, L.#, Siler, S.Q